ArticleFrontiers in cell and developmental biology2021
Combined Administration of Metformin and Atorvastatin Attenuates Diabetic Cardiomyopathy by Inhibiting Inflammation, Apoptosis, and Oxidative Stress in Type 2 Diabetic Mice.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 77 citations in OpenAlex.
- Inflammatory signalling in diabetic cardiomyopathy: molecular mechanisms and potential therapeutic strategies.Nature reviews. Cardiology · 2026Review
- DualKG-DC: A Drug-Centric Dual-Layer Knowledge Graph Framework for Drug Combination Prediction.Journal of medical systems · 2026Article
- Metformin alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy.Journal of molecular and cellular cardiology plus · 2025Article
- Diabetic cardiomyopathy: a comprehensive review of diagnosis, management, and future directions.Diabetology & metabolic syndrome · 2025Review
- Obesity indicators mediate the association between the aggregate index of systemic inflammation (AISI) and type 2 diabetes mellitus (T2DM).Lipids in health and disease · 2025Article
- Evaluation of the toxicity potential of exercise and atorvastatin/metformin combination therapy on STZ-diabetic rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control.Acta pharmacologica Sinica · 2025Article
- NLRP3 inflammasomes pathway: a key target for Metformin.Inflammopharmacology · 2025Review
- Electroacupuncture relieves type 2 diabetes by regulating gut microbiome.World journal of diabetes · 2025Article
- Diabetic Cardiomyopathy: An Update on Emerging Pathological Mechanisms.Current cardiology reviews · 2025Review
- Metformin Attenuates Myocardial Ischemia-Reperfusion Injury in Rats by Modulating JNK Pathway and Inhibiting PANoptosis Mechanisms.Cardiovascular therapeutics · 2025Article
- Molecular Pathways in Diabetic Cardiomyopathy and the Role of Anti-hyperglycemic Drugs Beyond Their Glucose Lowering Effect.Journal of lipid and atherosclerosis · 2025Review
- Impact of statin use on short- and long-term outcomes in patients with sepsis-induced myocardial injury: insights from the MIMIC-IV database.Frontiers in pharmacology · 2025Article
- Metformin improves cognitive dysfunction through SIRT1/NLRP3 pathway-mediated neuroinflammation in db/db mice.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Semaglutide attenuates pathological electrophysiological remodeling in diabetic cardiomyopathy via restoring Cx43 expression.Endocrine · 2024Article
- Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics.Asian journal of pharmaceutical sciences · 2024Review
- Review
- Article
- Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot study.Frontiers in medicine · 2024Article
- Liraglutide Improves Diabetic Cardiomyopathy by Downregulation of Cardiac Inflammatory and Apoptosis Markers.Current drug research reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic cardiomyopathy (DCM), a common complication of diabetes mellitus, may eventually leads to irreversible heart failure. Metformin is the cornerstone of diabetes therapy, especially for type 2 diabetes. Statins are widely used to reduce the risk of cardiovascular diseases. In this study, we aimed to investigate whether the combined administration of metformin and atorvastatin could achieve superior protective effects on DCM and to elucidate its molecular mechanism. Here,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.